GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 61-72 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Creatine for glucagon-like peptide-1-associated muscle loss.

Ostojic SM; Galyean S

Jan 1, 2026Clinical nutrition (Edinburgh, Scotland)

2026PubMedDirectly related

Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.

Orandi BJ; Yan L; Levan ML; Lofton HF; Chhabra KR; Ren-Fielding CJ; Husain SA; McAdams-DeMarco MA; Segev DL; Mankowski MA; Massie AB

Jan 1, 2026Obesity (Silver Spring, Md.)

2026PubMedDirectly related

Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis.

Alanizi AH; Alruwythi GM; Alotaibi NH; Alanazi NH; Alghurabi AM; Qubaiban R; Alsubaie N

Jan 1, 2026Frontiers in pediatrics

2026PubMedDirectly related

GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.

Malluhi M; Al-Naemi A; Akhtar S

Jan 1, 2026Biomolecules & biomedicine

2026PubMedDirectly related

Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.

Mehetre KN; Dawane JS

Jan 1, 2026Frontiers in endocrinology

2026PubMedSupporting evidence

Pulsatile liraglutide on a biased tirzepatide background: a hypothesis.

Kopitovic I

Jan 1, 2026Frontiers in endocrinology

2026PubMedDirectly related

Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.

Lubo C; Bustamante R; Quintana L; Guillen-Burgos HF

Jan 1, 2026Brain sciences

2026PubMedDirectly related

Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes.

Gupta K; Zeinali M; Altschul D; Agarwal V; Karsy M

Jan 1, 2026Pituitary

2026PubMedDirectly related

GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.

Jiang W; Fukunaga K; Kobayashi T; Saheki T; Yoshimura T; Zhang H; Ly R; Imachi H; Murao K

Jan 1, 2026International journal of molecular sciences

2026PubMedDirectly related

Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.

Salim H; Qureshi S; Gulsin GS; Khan HR; Waqas SA; McCann GP; Garg A; Shurrab M; Khunti K; Rashid M

Jan 1, 2026Diabetes, obesity & metabolism

2026PubMedDirectly related

The Role and Mechanism of Incretins in Gynaecologic Diseases.

Yan J; Cao M; Ding Y; Zhang Y; Sun Y; Jiang G; Zhang Y; Kang L; Zhou X; Luo J; Li B

Jan 1, 2026Endocrinology, diabetes & metabolism

2026PubMedDirectly related

New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.

Panou T; Gouveri E; Popovic DS; Papanas N

Jan 1, 2026Diabetes therapy : research, treatment and education of diabetes and related disorders